Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412.

Affiliation

Nowakowski GS(1), Hong F(2), Scott DW(3), Macon WR(4), King RL(4), Habermann TM(1), Wagner-Johnston N(5), Casulo C(6), Wade JL(7), Nagargoje GG(8), Reynolds CM(9), Cohen JB(10), Khan N(11), Amengual JE(12), Richards KL(13)(14), Little RF(15), Leonard JP(13), Friedberg JW(6), Kostakoglu L(16), Kahl BS(17), Witzig TE(1).
Author information:
(1)Division of Hematology, Mayo Clinic, Rochester, MN.
(2)Department of Data Sciences, Dana Farber Cancer Institute, Boston, MA.
(3)British Columbia Cancer Center for Lymphoid Cancer, Vancouver, Canada.
(4)Division of Hematopathology, Mayo Clinic Rochester MN.
(5)Johns Hopkins University, Baltimore, MD.
(6)University of Rochester, NY.
(7)Heartland NORP, Decatur IL.
(8)Marcy Hospital, Coon Rapids, MN.
(9)Saint Joseph Mercy Hospital, Ann Arbor, MI.
(10)Emory University-Winship Cancer Institute, Atlanta, GA.
(11)Fox Case Cancer Center, Philadelphia, PA.
(12)Columbia University Medical Center, New York, NY.
(13)Weill Cornell Medicine, New York, NY.
(14)Deceased.
(15)National Cancer Institute, Bethesda, MD.
(16)University of Virginia, Charlottesville VA.
(17)Department of Medicine, Washington University School of Medicine, St Louis, MO.

Abstract

Comment in J Clin Oncol. 2021 Apr 20;39(12):1314-1316.